Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse eventsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This prospective observational study examined whether gut microbiota composition is associated with immune responses and adverse events following SARS-CoV-2 vaccination. Researchers compared recipients of the inactivated CoronaVac vaccine with recipients of the mRNA BNT162b2 vaccine. They performed shotgun metagenomic sequencing on stool samples and measured immune markers using a surrogate virus neutralization test and a spike receptor-binding domain IgG ELISA.
Who was studied?
The study included 138 adult COVID-19 vaccinees, comprising 37 recipients of CoronaVac and 101 recipients of BNT162b2. Stool samples were collected from each participant at baseline and again one month after the second vaccine dose. The abstract does not specify additional demographic details such as age range or geographic location.
What were the most important findings?
CoronaVac recipients showed a significantly lower immune response than BNT162b2 recipients. Among CoronaVac vaccinees, higher neutralizing antibody levels were persistently associated with greater abundance of Bifidobacterium adolescentis, and their baseline gut microbiome was enriched in carbohydrate metabolism pathways. In BNT162b2 vaccinees, neutralizing antibody levels correlated positively with the total abundance of bacteria bearing flagella and fimbriae, including Roseburia faecis.
What are the greatest implications of this study?
The findings suggest that baseline and post-vaccination gut microbiota composition may help explain individual variation in vaccine-induced immune responses. Specific taxa such as Bifidobacterium adolescentis and Roseburia faecis, along with related metabolic pathways, could serve as candidate biomarkers or targets for improving vaccine immunogenicity. These associations may differ by vaccine platform, since inactivated and mRNA vaccines showed distinct microbial correlates of response.